Company: KROS
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001664710-25-000089
Chunk: 248

Company: Keros Therapeutics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Item 1
Chunk 248
---
.

19

In addition, we may incur other charges or cash expenditures not currently contemplated due to unanticipated events that may occur, including in connection with the implementation of the 2025 Restructuring.Accrued compensation and benefits costs as of September 30, 2025 and December 31, 2024 is as follows (in thousands):RESTRUCTURING LIABILITYBalance as of December 31, 2024— Expenses incurred2,971 Cash payments(1,329)Balance as of September 30, 20251,642 

14. SUBSEQUENT EVENTS

Share RepurchasesOn October 15, 2025, the Company entered into stock purchase agreements with certain entities affiliated with ADAR1 Capital Management (the “ADAR1 Parties”, and such stock purchase agreement, the “ADAR1 Repurchase Agreement”) and certain entities affiliated with Pontifax Venture Capital (collectively, the “Pontifax Parties”, and such stock purchase agreement, the “Pontifax Repurchase Agreement” and, together with the ADAR1 Repurchase Agreement, the “Repurchase Agreements”) to repurchase the shares of common stock held by the ADAR1 Parties and the Pontifax Parties, respectively, at a price of $17.75 per share. Pursuant to the terms and conditions of the Repurchase Agreements, the ADAR1 Parties and the Pontifax Parties sold all of the shares of common stock beneficially owned by them, being an aggregate of 10,176,595 shares of common stock, to the Company at a per share purchase price of $17.75 per share, for an aggregate purchase price of $180.6 million. In October 2025, the Company also announced that it plans to distribute 25% of any net cash proceeds it receives on or before December 31, 2028 from the Takeda Agreement to its stockholders.Commencement of Issuer Tender OfferOn October 20, 2025, the Company announced the commencement of an issuer tender offer to repurchase shares of its common stock for an aggregate cash purchase price of up to $194.4 million, at a cash purchase price of $17.75 per share, subject to market conditions and upon the terms and conditions set forth in the tender offer documents that were filed with the SEC on October 20, 2025.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following